NASDAQ:BBLG Bone Biologics (BBLG) Stock Price, News & Analysis $0.39 +0.00 (+1.14%) As of 01:54 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC Filings About Bone Biologics Stock (NASDAQ:BBLG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bone Biologics alerts:Sign Up Key Stats Today's Range$0.39▼$0.4150-Day Range$0.39▼$0.9352-Week Range$0.38▼$2.66Volume51,351 shsAverage Volume149,227 shsMarket Capitalization$1.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Bone Biologics Corporation (NASDAQ: BBLG) is a biotechnology company focused on developing regenerative medicine products for the orthopedic and spine markets. Its work centers on bone growth and spinal fusion, where physicians use biologic materials and implants to help stabilize the spine and support the formation of new bone. The company’s primary technology is based on NELL-1, a recombinant human protein that has demonstrated bone-forming properties in preclinical and clinical research. Bone Biologics has been developing NELL-1-based products, including bone graft substitutes intended for use with spinal fusion procedures. The company’s strategy is to combine its biologic technology with established scaffold materials and delivery systems to create products designed to promote bone regeneration. Bone Biologics has historically operated as a development-stage biotechnology company and has focused its research and commercialization efforts primarily on the United States spine and orthopedic markets. Its products remain subject to clinical development and regulatory approval, and the company has not established a broad portfolio of commercially marketed products based on the available information.AI Generated. May Contain Errors. Read More Bone Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreBBLG MarketRank™: 1.05878510777 of 5 starsBone Biologics scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBone Biologics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBone Biologics has only been the subject of 1 research reports in the past 90 days.Read more about Bone Biologics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Bone Biologics are expected to grow in the coming year, from ($1.23) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bone Biologics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bone Biologics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBone Biologics has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Bone Biologics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.89% of the float of Bone Biologics has been sold short.Short Interest Ratio / Days to CoverBone Biologics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bone Biologics has recently increased by 38.10%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBone Biologics does not currently pay a dividend.Dividend GrowthBone Biologics does not have a long track record of dividend growth. News and Social Media3.6 / 5News SentimentN/A News SentimentBone Biologics has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Bone Biologics this week, compared to 2 articles on an average week.Search Interest1 people have searched for BBLG on MarketBeat in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bone Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders5.00% of the stock of Bone Biologics is held by insiders.Percentage Held by Institutions34.30% of the stock of Bone Biologics is held by institutions.Read more about Bone Biologics' insider trading history. Receive BBLG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bone Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBLG Stock News HeadlinesBone Biologics Expands Trial SitesSeptember 8, 2026 | globenewswire.comBone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 3, 2026 | globenewswire.comWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run, and Vertiv before a 1900 percent run. Now he's tracking a radical light-speed technology that could make AI 100 times faster and 100 times more energy efficient. Stocks tied to it have already climbed 133 percent, 217 percent, and 320 percent.October 16 at 1:00 AM | Brownstone Research (Ad)BBLG Efficiency Improves as Crucial Trials AdvanceAugust 17, 2026 | finance.yahoo.comBone Biologics extends rhNELL-1 validated shelf life to 32 months as NB1 study advancesAugust 12, 2026 | msn.comBone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1August 12, 2026 | globenewswire.comBone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 PrioritiesJuly 23, 2026 | globenewswire.comBBLG Secures Financing for Critical TrialsJuly 8, 2026 | finance.yahoo.comSee More Headlines BBLG Stock Analysis - Frequently Asked Questions How have BBLG shares performed this year? Bone Biologics' stock was trading at $1.45 at the start of the year. Since then, BBLG shares have decreased by 73.1% and is now trading at $0.39. How were Bone Biologics' earnings last quarter? Bone Biologics Corp. (NASDAQ:BBLG) announced its quarterly earnings data on Friday, August, 14th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.04. When did Bone Biologics' stock split? Bone Biologics's stock reverse split on Tuesday, June 10th 2025.The 1-6 reverse split was announced on Monday, June 9th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 9th 2025. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. When did Bone Biologics IPO? Bone Biologics (BBLG) raised $8 million in an IPO on Wednesday, October 13th 2021. The company issued 1,510,455 shares at $5.25 per share. How do I buy shares of Bone Biologics? Shares of BBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/14/2026Today10/16/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (14m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 BBLG's financial health is in the Red zone, according to TradeSmith. BBLG has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:BBLG Previous SymbolNASDAQ:BBLG CIK1419554 Webwww.bonebiologics.com Phone781-552-4452FaxN/AEmployees2Year Founded2004Profitability EPS (Trailing Twelve Months)($1.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.11 million Net MarginsN/A Pretax MarginN/A Return on Equity-57.87% Return on Assets-53.65% Debt Debt-to-Equity RatioN/A Current Ratio8.67 Quick Ratio8.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / Book0.13Miscellaneous Outstanding Shares2,760,000Free Float2,618,000Market Cap$1.08 million OptionableNot Optionable Beta0.90 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:BBLG) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersYFT Could Be Building the Future of Drug Discovery!MindWalk Holdings (NASDAQ: HYFT) is applying AI to drug discovery, and its customer base already includes 19 o...Trading Wire | SponsoredMelting The GodsChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | Sponsored$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bone Biologics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bone Biologics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
